CompletedNAResults postedLast updated 26 September 2025
What this trial tests
NA trial testing Practical Resources for Effective Postpartum Parenting (PREPP) in Postpartum Depression (PPD) in 216 participants. Completed in 28 February 2024.
Timeline
12 February 2018
Primary endpoint 28 February 2024
28 February 2024
Quick facts
Lead sponsor
Columbia University
Phase
NA
Status
Completed
Study type
INTERVENTIONAL
Allocation
randomized
Design
parallel
Masking
single
Primary purpose
prevention
Enrollment
216
Start date
12 February 2018
Primary completion
28 February 2024
Estimated completion
28 February 2024
Sites
1 location across United States
Drugs / interventions tested
Practical Resources for Effective Postpartum Parenting (PREPP)
Adults 18 to 45, female only, with Postpartum Depression (PPD). Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Score on the Edinburgh Postnatal Depression Scale (EPDS)Primary· Baseline, 6 weeks, 12 weeks, and 16 weeks postpartum
Maternal mood: Postpartum Depression Symptoms will be measured by Edinburgh Postnatal Depression Scale (EPDS). The EPDS is a 10-item questionnaire that was developed to identify women who have postpartum depression. Items of the scale correspond to various clinical depression symptoms, such as guilt feeling, sleep disturbance, low energy, anhedonia, and suicidal ideation. Overall assessment is done by total score, which is determined by adding together the scores for each of the 10 items. Scores range from 0 to 30, with higher scores indicate more depressive symptoms (worse outcome).
Baseline
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
5.04
± 0.49
Enhanced Treatment as Usual
4.36
± 3.51
6 week
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
4.43
± 0.46
Enhanced Treatment as Usual
4.04
± 0.42
12 week
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
3.51
± 0.39
Enhanced Treatment as Usual
3.74
± 0.42
16 week
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
3.69
± 0.41
Enhanced Treatment as Usual
4.04
± 0.44
Score on the Pittsburgh Sleep Quality Index (PSQI)Primary· Baseline, 6 weeks, 12 weeks, and 16 weeks postpartum
Maternal perception of sleep quality: The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire that assesses sleep quality and disturbances over a 1-month time interval. A total of 19 individual items generate 7 "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Scores range from 0 to 21, where lower scores indicate a healthier sleep quality (better outcome).
Baseline
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
7.01
± 0.37
Enhanced Treatment as Usual
6.55
± 0.35
6 week
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
7.21
± 0.43
Enhanced Treatment as Usual
8.16
± 0.47
12 week
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
5.73
± 0.40
Enhanced Treatment as Usual
6.48
± 0.44
16 week
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
5.88
± 0.39
Enhanced Treatment as Usual
6.06
± 0.40
Score on HRSD-24Primary· Baseline, 6 weeks, 12 weeks, and 16 weeks postpartum
The Hamilton Rating Scale for Depression (HRSD), also called the Hamilton Depression Rating Scale (HDRS), sometimes also abbreviated as HAM-D, is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery. The patient is rated on 24 items scored either on a 3-point (0-2) or 5-point (0-4) Likert-type scale. Total scores range from 0 to 74 with a lower score indicating a better outcome.
Baseline
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
4.09
± 0.39
Enhanced Treatment as Usual
3.16
± 0.32
6 week
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
3.23
± 0.34
Enhanced Treatment as Usual
2.99
± 0.32
12 week
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
2.99
± 0.34
Enhanced Treatment as Usual
3.31
± 0.37
16 week
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
2.74
± 0.31
Enhanced Treatment as Usual
2.73
± 0.31
Score on the PHQ-9Primary· Baseline, 6 weeks, 12 weeks, and 16 weeks postpartum
The nine-item Patient Health Questionnaire (PHQ-9) is a depressive symptom scale and diagnostic tool introduced in 2001 to screen adult patients in primary care settings. The instrument assesses for the presence and severity of depressive symptoms and a possible depressive disorder. It is scored by simply adding up the individual items' scores. Scores range from 0 to 27 with a lower score indicating a better outcome.
Baseline
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
6.36
± 0.49
Enhanced Treatment as Usual
5.64
± 0.45
6 week
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
5.21
± 0.44
Enhanced Treatment as Usual
5.42
± 0.46
12 week
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
4.13
± 0.39
Enhanced Treatment as Usual
5.19
± 0.47
16 week
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
4.50
± 0.41
Enhanced Treatment as Usual
4.08
± 0.38
Hamilton Anxiety Scale (HRSA)Primary· Baseline, 6 weeks, 12 weeks, and 16 weeks postpartum
The scale consists of 14 items designed to assess the severity of a patient's anxiety. The patient is rated by on 14 items scored on a 5-point (0-4) Likert-type scale. Total scores range from 0 to 56 with a lower score indicating a better outcome.
Baseline
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
4.09
± 0.41
Enhanced Treatment as Usual
3.63
± 0.37
6 week
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
3.01
± 0.33
Enhanced Treatment as Usual
3.09
± 0.34
12 week
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
3.01
± 0.35
Enhanced Treatment as Usual
3.30
± 0.38
16 week
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
2.93
± 0.34
Enhanced Treatment as Usual
2.94
± 0.34
Sleep Efficiency (SEact) of the MothersPrimary· 28-32 weeks gestation (prenatal), 34-39 weeks gestation (prenatal), 6 weeks postpartum, 16 weeks postpartum
Sleep Efficiency (SEact) was measured by an activity monitor worn by the participants continuously over 7 days. SEact is reported as a percent of time spent asleep during the total time spent in bed.
28-32 weeks gestation
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
71.90
± 21.25
Enhanced Treatment as Usual
73.44
± 25.21
34-39 weeks gestation
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
74.00
± 22.67
Enhanced Treatment as Usual
71.28
± 24.31
6 week postpartum
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
65.32
± 25.55
Enhanced Treatment as Usual
71.14
± 20.78
16 week postpartum
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
69.25
± 22.24
Enhanced Treatment as Usual
76.74
± 17.91
Total Nocturnal Sleep Duration - Brief Infant Sleep Questionnaire (BISQ)Secondary· 6 weeks and 16 weeks postpartum
The BISQ is a parent-reported questionnaire on infants/toddler (0-29 months) sleep over 7 days
6 weeks
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
7.27
± 2.08
Enhanced Treatment as Usual
7.26
± 1.97
16 weeks
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
8.24
± 2.12
Enhanced Treatment as Usual
8.30
± 1.79
Total Daytime Sleep Duration - Brief Infant Sleep Questionnaire (BISQ)Secondary· 6 weeks and 16 weeks postpartum
The BISQ is a parent-reported questionnaire on infants/toddler (0-29 months) sleep over 7 days.
6 weeks
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
6.17
± 2.66
Enhanced Treatment as Usual
6.65
± 2.47
16 weeks
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
4.84
± 2.45
Enhanced Treatment as Usual
4.50
± 1.87
Total Number of Instances of Waking up at Night - Brief Infant Sleep Questionnaire (BISQ)Secondary· 6 weeks and 16 weeks postpartum
The BISQ is a parent-reported questionnaire on infants/toddler (0-29 months) sleep over 7 days.
6 weeks
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
2.61
± 1.05
Enhanced Treatment as Usual
2.71
± 1.17
16 weeks
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
1.77
± 1.08
Enhanced Treatment as Usual
1.85
± 1.26
Total Settling Time to Fall Asleep for the Night - Brief Infant Sleep Questionnaire (BISQ)Secondary· 6 weeks and 16 weeks postpartum
The BISQ is a parent-reported questionnaire on infants/toddler (0-29 months) sleep over 7 days.
6 weeks
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
41.23
± 35.04
Enhanced Treatment as Usual
31.35
± 20.16
16 weeks
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
31.21
± 22.50
Enhanced Treatment as Usual
32.23
± 30.07
Daily Minutes of Infant Crying Over 4 DaysSecondary· 6 weeks and 16 weeks postpartum
Cry behavior will be measured by The Baby Day Diary, which is a 24-hour diary of infant and parental behavior for days. The number of minutes for the crying behavior is averaged over a span of 4 days, with a higher number indicating a worse outcome.
6 weeks
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
164.72
± 81.32
Enhanced Treatment as Usual
117.35
± 72.46
16 weeks
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
98.75
± 66.58
Enhanced Treatment as Usual
101.25
± 48.23
Length of Longest Sleep at Night for Infants Over 4 DaysSecondary· 6 weeks and 16 weeks postpartum
Sleep behavior will be measured by The Baby Day Diary, which is a 24-hour diary of infant and parental behavior for days. The number of minutes of sleep is averaged over a span of 4 days. A higher number indicates a better outcome.
6 weeks
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
249.52
± 81.04
Enhanced Treatment as Usual
238.24
± 106.78
16 weeks
Group
Value
95% CI
Practical Resources for Effective Postpartum (PREPP)
291.52
± 71.91
Enhanced Treatment as Usual
277.67
± 74.33
Sponsor's own description
The primary aim of this study is to determine if a behavioral intervention targeting maternal caregiving of young infants can increase infant sleep and reduce fuss/cry behavior, and thereby (1) reduce the incidence and/or severity of postpartum maternal depression and (2) improve the quality of the mother-infant interaction and subsequent child development. Specifically, the study team will investigate: (1) the effectiveness of the intervention compared to usual care; (2) if the effects of the intervention can be detected in the assessments of the quality of mother-infant interaction; (3) if there are prenatal and/or postnatal biomarkers that can help identify infants whose behavior is more likely to play a role in their mothers' depression; (4) if these markers differentiate which infants will be most responsive to the intervention(s); and (5), if assessments of brain function at birth and at 4-6 weeks of age provide biological nodal points for identifying the effects of the intervention on infant brain development. Participants will be recruited during their 2nd trimester, and will be randomly separated into one of two groups: a group that receives coaching in parenting techniques 3 coaching sessions and 2 check-in sessions or one that receives treatment as usual.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Postpartum Depression (PPD)
Currently open trials in the same condition.
NCT07384273 — Evaluating the Effectiveness of an Internet-based Therapy (iCARE) to Treat Symptoms of Postpartum Depression
· NA
· recruiting
NCT07210255 — SAINT in Postpartum Depression (PPD)
· NA
· recruiting
NCT07077759 — An Online Self-compassion Intervention for Anxiety and Depression in Fathers of Infants: A Feasibility Study
· NA
· active not recruiting
NCT07272252 — Narrative Nursing for Cesarean Mothers' Anxiety and Breastfeeding Confidence
· NA
· recruiting
NCT07300176 — Virtual Reality-Assisted Intraoperative Sensory Modulation on Postpartum Depression and the Kynurenine Pathway
· active not recruiting
Other Columbia University trials
Trials by the same sponsor.
NCT06558422 — Human Models of Selective Insulin Resistance: Pancreatic Clamp
· Phase 1
· not yet recruiting
NCT07264582 — HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking
· NA
· not yet recruiting
NCT05992415 — Know Your Pressures NYC
· NA
· not yet recruiting
NCT05645211 — The AgRP and GH/IGF-1 Axis in Children
· not yet recruiting
NCT07403604 — Effect of Insulin Lowering on Lipogenesis
· Phase 1
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Columbia University
Last refreshed: 26 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03283254.